Ophthalmic Compositions and Medical Uses Thereof in Treatment of Myopia
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
A61K-036/704
A61K-036/536
A61K-009/00
A61P-027/02
출원번호
16431248
(2019-06-04)
공개번호
20200384053
(2020-12-10)
발명자
/ 주소
Wan, Lei
출원인 / 주소
Wan, Lei
인용정보
피인용 횟수 :
0인용 특허 :
0
초록
The invention relates to ophthalmic compositions containing an aqueous extract derived from Polygonum cuspidatum Sieb. et Zucc. and/or an aqueous extract derived from Prunella vulgaris. The invention further relates to the use of the ophthalmic compositions in the treatment of myopia.
대표청구항▼
1. An ophthalmic composition comprising a therapeutically effective amount of an aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable
1. An ophthalmic composition comprising a therapeutically effective amount of an aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable carrier. 2. The composition according to claim 1, which consists essentially of a therapeutically effective amount of the aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable carrier. 3. The composition according to claim 2, which consists of a therapeutically effective amount of the aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable carrier. 4. The composition according to claim 1, wherein the aqueous extract is obtained using an aqueous solvent selected from water, C1-6 alkanols, C1-4 alkylene glycols, aqueous carbohydrate solutions, salt solutions thereof, and mixtures thereof. 5. The composition according to claim 4, wherein the aqueous solvent is selected from water and salt solutions thereof. 6. The composition according to claim 5, wherein the ophthalmic composition is formulated into a dosage form selected from the group consisting of an eye drop, an eye wash, an eye spray, an ointment, a cream and a gel. 7. The composition according to claim 6, wherein the ophthamically acceptable carrier is selected from the group consisting of polyoxyethylene castor oil ether (Cremophor EL), alkyl dimethyl benzyl ammonium (BKC), lecithin, cholesterol, phosphate-buffered saline (PBS), cyclodextrin, tween 80, castor oil, artificial tears, and a combination thereof. 8. The composition according to claim 7, wherein the ophthalmically acceptable carrier comprises artificial tears. 9. A method for treating myopia in a subject, comprising administering to said subject an ophthalmic composition comprising a therapeutically effective amount of an aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable carrier. 10. The method according to claim 9, wherein the ophthalmic composition consists essentially of a therapeutically effective amount of the aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable carrier. 11. The method according to claim 10, wherein the ophthalmic composition consists of a therapeutically effective amount of the aqueous extract derived from a botanical species selected from the group consisting of Polygonum cuspidatum Sieb. et Zucc., Prunella vulgaris, and a combination thereof, in combination with an ophthalmically acceptable carrier. 12. The method according to claim 9, wherein the aqueous extract is obtained using an aqueous solvent selected from water, C1-6 alkanols, C1-4 alkylene glycols, aqueous carbohydrate solutions, salt solutions thereof, and mixtures thereof. 13. The method according to claim 12, wherein the aqueous solvent is selected from water and salt solutions thereof. 14. The method according to claim 13, wherein the ophthalmic composition is formulated into a dosage form selected from the group consisting of an eye drop, an eye wash, an eye spray, an ointment, a cream and a gel. 15. The method according to claim 14, wherein the ophthamically acceptable carrier is selected from the group consisting of polyoxyethylene castor oil ether (Cremophor EL), alkyl dimethyl benzyl ammonium (BKC), lecithin, cholesterol, phosphate-buffered saline (PBS), cyclodextrin, tween 80, castor oil, artificial tears, and a combination thereof. 16. The method according to claim 15, wherein the ophthalmically acceptable carrier comprises artificial tears. 17. The method according to claim 16, wherein the subject is selected from the group consisting of human and non-human vertebrates. 18. The method according to claim 17, wherein the subject is human. 19. The method according to claim 18, wherein the ophthalmic composition is administered at an amount ranging from 0.01 ng/kg body weight/day to 100 ng/kg body weight/day. 20. The method according to claim 19, wherein the ophthalmic composition is administered at an amount ranging from 0.1 ng/kg body weight/day to 10 ng/kg body weight/day.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.